Medine.co.uk

Carporal 160 Mg Tablets For Dogs

AN: 00449/2014

Issued: August 2015

SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


Carporal 160 mg tablets for dogs

(AT, BE, CY, CZ, EL, ES, FR, HR, HU, IE, IT, LU, NL, PT, RO, SI, SK, UK)

Canicaral vet 160 mg tablets for dogs

(DK, FI, IS, NO, SE, EE, LT, LV, PL)


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


1 tablet contains:


Active substance:

Carprofen 160 mg

For the full list of excipients, see section 6.1.


3. PHARMACEUTICAL FORM


Tablet.

Light brown with brown spots, round and convex flavoured tablet with a cross-shaped break line on one side.

Tablets can be divided into 2 or 4 equal parts.


4. CLINICAL PARTICULARS


4.1 Target species


Dogs.


4.2 Indications for use, specifying the target species


Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow up to parenteral analgesia in the management of post-operative pain.


4.3 Contraindications


Do not use in cats.

Do not use in pregnant or lactating bitches.

Do not use in dogs less than 4 months of age.

Do not use in case of hypersensitivity to active substance or to any of the excipients.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia.


4.4 Special warnings for each target species


Refer to sections 4.3 and 4.5.


4.5 Special precautions for use


Special precautions for use in animals

Use in aged dogs may involve additional risk.

If such a use cannot be avoided, dogs may require careful clinical management.

Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.


See section 4.8.


Special precautions to be taken by the person administering the veterinary medicinal product to animals

In the event of accidental ingestion of the tablets, seek medical advice and show the package leaflet or the label to the physician. Wash hands after handling the product.


4.6 Adverse reactions (frequency and seriousness)


Typical undesirable effects associated with NSAIDs such as vomiting, soft faeces/diarrhea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.


If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought.


As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.


4.7 Use during pregnancy and/or lactation


Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches.


4.8 Interaction with other medicinal products and other forms of interaction


Do not administer other NSAIDs and glucocorticoids concurrently or within 24 hours of administration of the product. Carprofen is highly bound to plasma proteins and may compete with other highly bound drugs, which can lead to toxic effects.


Concurrent administration of potential nephrotoxic drugs should be avoided.


4.9 Amounts to be administered and administration route


For oral administration.

To ensure a correct dosage body weight should be determined as accurately as possible to avoid overdosing.


Dosage

2-4 mg carprofen per kg bodyweight per day.

For reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease: an initial dose of 4 mg carprofen per kg bodyweight per day given as a single daily dose or in two equally divided doses may, subject to clinical response, be reduced to 2 mg carprofen/kg bodyweight/day given as a single dose. Duration of treatment depends on the response observed in the patient. For treatment beyond 14 days the dog should be regularly examined by a veterinarian.

Do not exceed the recommended dosage.

To extend analgesic and anti-inflammatory cover post-operatively,parenteral preoperative treatment with an injectable carprofen product may be followed by carprofen tablets at 4 mg/kg bw/day for up to 5 days.


The following table is intended as a guide to dispensing the product at the dose rate of 4 mg per kg bodyweight per day.




Number of tablets for a dose rate of 4 mg/kg bw

Body weight (kg)

Carporal 40 mg

Once daily

Carporal 40 mg

Twice daily

Carporal 160 mg

Once daily

Carporal 160 mg

Twice daily

>2.5kg - 5 kg




>5 kg - 7.5 kg


>7.5 kg - 10 kg


>10 kg - 12.5 kg


>12.5 kg - 15 kg



>15 kg - 17.5 kg



>17.5 kg - 20 kg



>20 kg - 25 kg

>25 kg - 30 kg



>30 kg -35 kg

>35 kg - 40 kg